Alteration of Interleukin 4 Production Results in the Inhibition of T Helper Type 2 Cell-dominated Inflammatory Bowel Disease in T Cell Receptor α Chain-deficient Mice

By Hideki Iijima,*† Ichiro Takahashi,* Daisuke Kishi,*§ Jin-Kyung Kim,* Sunao Kawano,‡ Masatsugu Hori,‡ and Hiroshi Kiyono*

Summary

T cell receptor α chain–deficient (TCR-α−/−) mice are known to spontaneously develop inflammatory bowel disease (IBD). The colitis that develops in these mice is associated with increased numbers of T helper cell (Th)2-type CD4+ TCR-ββ (CD4+ ββ) T cells producing predominantly interleukin (IL)-4. To investigate the role of these Th2-type CD4+ ββ T cells, we treated TCR-α−/− mice with anti–IL-4 monoclonal antibody (mAb). Approximately 60% of TCR-α−/− mice, including those treated with mock Ab and those left untreated, spontaneously developed IBD. However, anti–IL-4 mAb-treated mice exhibited no clinical or histological signs of IBD, and their levels of mucosal and systemic Ab responses were lower than those of mock Ab-treated mice. Although TCR-α−/− mice treated with either specific or mock Ab developed CD4+ ββ T cells, only those treated with anti–IL-4 mAb showed a decrease in Th2-type cytokine production at the level of mRNA and protein and an increase in interferon γ–specific expression. These findings suggest that IL-4–producing Th2-type CD4+ ββ T cells play a major immunopathological role in the induction of IBD in TCR-α−/− mice, a role that anti–IL-4 mAb inhibits by causing Th2-type CD4+ ββ T cells to shift to the Th1 type.

Key words: inflammatory bowel disease • T cell receptor α chain–deficient mice • interleukin 4 • mucosal immunity • pathogenic T cell • Th2-induced colitis

The etiopathogenesis of inflammatory bowel disease (IBD), a chronic and relapsing inflammation of the gastrointestinal tract, remains poorly understood. In an effort to elucidate the molecular and cellular mechanisms behind IBD (1-8), researchers in the last six years have used several specific gene-manipulated animal models, including TCR α chain–deficient (TCR-α−/−) mice, TCR-β−/− mice, MHC class II–deficient mice, IL-2–deficient mice, IL-10–deficient mice, IL-7–transgenic mice, Gαq–deficient mice, and severe combined immunodeficiency (SCID) mice restored with CD45RBhiCD4+ T cells. Of interest here are the TCR-α−/− mice, which spontaneously develop chronic colitis, a condition similar to ulcerative colitis in humans (2, 9, 10). About 60% of TCR-α−/− mice develop chronic diarrhea and anorectal prolapse under specific pathogen-free conditions at ~3-4 mo of age. Tissue sections from the diseased colons of these animals show infiltration of inflammatory cells and elongation of crypts. In addition, higher levels of Ab are found in the mucosa-associated tissues (e.g., mesenteric lymph nodes [MLNs], Peyer’s patches, and intestinal lamina propia [LP]) as well as in the systemic lymphoid organs (e.g., spleen [SP]) of these animals (9, 10).

Our own previous studies and those of other investigators have shown that CD4+ TCR-α−/β+ (CD4+ βdm) T cells develop in the mucosal and peripheral lymphoid tissues of TCR-α−/− mice with IBD (9-12). These CD4+ βdm T cells are considered to be pathogenic for the induction of IBD in this mouse model, since depletion of CD4+ βdm T cells by anti–TCR-β mAb prevents the onset of IBD (10). The pathogenic nature of these CD4+ βdm T cells is also evidenced by the lesser severity of IBD seen in...
TCR-β⁻/⁻ mice, from which CD4⁺βdim T cells are absent (2). Our previous study showed that CD4⁺βdim T cells produce a predominance of IL-4, suggesting a potential role for Th2-type responses in the development of IBD (10). However, the association between IL-4-producing Th2-type CD4⁺βdim T cells and IBD is still poorly understood. Since our most recent study has provided strong evidence that these CD4⁺βdim T cells use a ββ homodimeric form of TCR, this subset of T cells will be designated here as ββ T cells in order to reflect the unique characteristics of these pathologic lymphocytes (13).

In this study, TCR-α⁻/⁻ mice were treated with either anti-IL-4 mAb or mock Ab. In treated TCR-α⁻/⁻ mice, Ab responses in the serum and fecal extracts were strongly suppressed and cytokine production from CD4⁺ββ T cells was shifted from the Th2 to the Th1 type. In addition, morphological and histological studies showed no obvious signs of IBD in TCR-α⁻/⁻ mice treated with anti-IL-4 mAb. These findings provide new evidence that Th2-type CD4⁺ββ T cells can induce IBD. Conversion from a dominant Th2 to a Th1 environment resulted in the prevention of IBD in TCR-α⁻/⁻ mice.

Materials and Methods

Mice. TCR-α⁻/⁻ mice with a background of C57BL/6 were obtained from The Jackson Laboratory. The mice were originally generated by a targeted disruption of TCR genes in embryonic stem cells (2). They were housed in the Experimental Animal Facility at the Research Institute for Microbial Diseases, Osaka University, under specific pathogen-free conditions and received sterilized food and autoclaved distilled water ad libitum.

Anti-IL-4 mAb Treatment. In this study, a standard protocol was used for mAb in vivo treatment (10). TCR-α⁻/⁻ mice from 6 to 25 wk of age were intraperitoneally injected with rat anti-mouse IL-4 mAb (BVD4-1D11, 1 mg/mouse; PharMingen) or rat IgG2b (3.5-38, 1 mg/mouse; PharMingen) as mock Ab in 250 μl of PBS once a week. These treatments did not produce any signs of serum sickness.

Detection of Abs by ELISA. Levels of IgA, IgG, and IgM Ab in serum and fecal extracts at 25 wk of age were examined by ELISA as described previously (14). In brief, ELISA plates (Nunc) were coated with 100 μl of goat anti-mouse Ig (H + L) (Southern Biotechnology Associates) in PBS and were incubated for 16 h at 4°C. Serial twofold dilutions of sera or fecal extracts were added (100 μl/well). The plates were incubated with optimal concentrations of PE-conjugated anti-CD4 mAb (anti-L3T4; RM4-5) and FITC-conjugated anti-TCR-β mAb (H57-597) were obtained from PharMingen. Single-cell suspensions of lymphocytes (10⁶/sample) were then stained with optimal concentrations of PE-conjugated anti-CD4 mAb and FITC-conjugated anti-TCR-β mAb. These samples were subjected to flow cytometric analysis by using a FACScan™ (Becton Dickinson). Data were analyzed by using CellQuest software (Becton Dickinson).

For the analysis of the cytokine profile, CD4⁺ββ T cells were purified by FACS Vantage™ (Becton Dickinson).

Reverse-transcription PCR. Cytokine production by purified CD4⁺ββ T cells from colonic LP was analyzed by modified cytokine-specific reverse transcription (RT)-PCR as described (17, 18). To isolate RNA from the CD4⁺ββ T cells purified by flow cytometry, TRIzol reagent (GIBCO BRL) was used. Purified RNA was reverse transcribed into cDNA using Superscript II reverse transcriptase (GIBCO BRL) and DIG DNA Labeling Mix® (Boehringer Mannheim), which incorporates DIG-labeled dUTP every 20–25 nucleotides during reverse transcription. The DIG-labeled, synthesized cDNA and a series of diluted DIG-labeled control cDNA (Boehringer Mannheim) were dot blotted onto the nucleic acid transfer membrane (Amersham Pharmacia Biotech) and cross-linked by UV cross-linker (Spectronics). The membrane was subjected to blocking by 1% blocking reagent (GIBCO BRL) for 1 h at 25°C. DIG-labeled, synthesized cDNA and a series of diluted DIG-labeled control cDNA (Boehringer Mannheim) were dot blotted onto the nucleic acid transfer membrane (Amersham Pharmacia Biotech) and cross-linked by UV cross-linker (Spectronics). The membrane was subjected to blocking by 1% blocking reagent (Boehringer Mannheim) for 10 min. The membrane was then incubated with 1% chemiluminescent substrate for alkaline phosphatase (CDPStar™ (Tropix), in 100 mM Tris-HCl, 100 mM NaCl, 50 mM MgCl₂). The developed chemiluminescent signals on the membrane were exposed to an imaging screen for 18 h, and then characterized by an image analyzer (Molecular Imager™ system; Bio-Rad Laboratories). The images on the screen were extracted by a laser scanner, and the number of synthesized cDNA samples were quantitated using the image analyzer. PCR amplification of 10 ng of cDNA for each sample was performed with the GeneAmp PCR System 9700 (Perkin-Elmer Cetus). The cytokine-specific primers and
amplification protocols used have been described previously (18). The amplified products were separated by electrophoresis in 1.8% agarose gel and were visualized with ethidium bromide (18). The amplified products were separated by electrophoresis.

Results

Anti-IL-4 mAb treatment blocked aberrant Ig production in TCR-α−/− mice. As increased levels of Abs are one of the immunological features of TCR-α−/− mice with IBD (10), we sought to determine and compare the levels of serum and fecal IgA, IgG, and IgM Abs in anti-IL-4 mAb- and mock Ab-treated TCR-α−/− mice at 25 wk of age by using ELISA. Serum as well as fecal Ab titers were increased in mock Ab-treated TCR-α−/− mice (Fig. 1 A). The levels of Ab titers in these mice were comparable to those of untreated mice, as observed in previous reports (9, 10). However, the levels of IgA, IgG, and IgM Abs in serum and fecal extracts were significantly decreased in TCR-α−/− mice treated with anti-IL-4 mAb (P < 0.01; Fig. 1 A). When IgG subclass Ab titers of TCR-α−/− mice treated with anti-IL-4 mAb were examined by ELISA, levels of IgG1 and IgG2b were found to have decreased and those of IgG2a to have increased significantly (P < 0.01; Fig. 1 B).

Inhibition of B cell development in TCR-α−/− mice by Anti-IL-4 mAb treatment. To further confirm the reduction of Ab production at the cellular level, mononuclear cells were isolated from systemic and mucosal tissues of TCR-α−/− mice treated with anti-IL-4 mAb and mock Ab for subsequent ELISPOT assay. The numbers of Ab-forming cells were increased in the systemic lymphoid (e.g., SP) as well as in mucosa-associated tissues (e.g., MLNs, colonic LP) of TCR-α−/− mice treated with mock Ab (Fig. 2). On the other hand, numbers of IgA, IgG, and IgM Ab-forming cells from TCR-α−/− mice treated with anti-IL-4 mAb were significantly decreased both in the systemic lymphoid and mucosa-associated tissues (P < 0.01; Fig. 2).

Anti-IL-4 mAb did not influence the development of CD4+ββ T cells. Since the administration of anti-IL-4 mAb inhibited Ab production in TCR-α−/− mice (Figs. 1 and 2), we next used flow cytometry to assess the influence of mAb treatment on the development of CD4+ββ T cells. A subset of CD4+ββ T cells costained with PE-conjugated anti-CD4 mAb (RM4-5) and FITC-conjugated anti-TCR-β (H57-597) was detected in the mucosal and peripheral tissues of mock Ab–treated TCR-α−/− mice. Surprisingly, a similar frequency of CD4+ββ T cells also developed in TCR-α−/− mice treated with anti-IL-4 mAb (Fig. 3). Additionally, the number of total lymphocytes in colonic LP obtained by dissociation with collagenase showed no statistical change between the two groups of mice (Mock Ab, 4.4 ± 0.8 × 10^6 cells/mouse; and anti-IL-4 mAb, 4.0 ± 0.6 × 10^6 cells/mouse). Further, mice treated with anti-IL-4 mAb did not show obvious clinical signs of IBD (see section below). These findings show that
anti-IL-4 mAb treatment did not influence the development of CD4+ββ T cells.

Anti-IL-4 mAb Treatment Altered the Cytokine Profile of CD4+ββ T Cells from Dominant Th2 to Th1 Type. As the development of aberrant CD4+ββ T cells was not affected by treatment with anti-IL-4 mAb (Fig. 3), we next analyzed the cytokine profile of CD4+ββ T cells isolated from TCR-α−/− mice treated with anti-IL-4 mAb or mock Ab. The CD4+ββ T cells were isolated from the colonic LP of TCR-α−/− mice by FACS Vantage™, and the profile of Th1 and Th2 cytokine expression was examined by cytokine-specific RT-PCR. Our previous study showed that CD4+ββ T cells could be considered to be of the Th2 phenotype, since a cytokine-specific ELISPOT assay showed that they produced IL-4 but not Th1 cytokines (10). This pattern of Th2-type cytokine production was also confirmed by cytokine-specific RT-PCR, since CD4+ββ T cells isolated from the colonic LP of mock Ab-treated TCR-α−/− mice expressed mRNA specific for IL-4, IL-5, IL-6, and IL-10, but not for Th1-type cytokines (Fig. 4). Conversely, in the TCR-α−/− mice treated with anti-IL-4 mAb, the pattern of cytokine production was significantly changed; namely, specific messages for Th2-type cytokines such as IL-4, IL-5, and IL-10 were not detected, whereas those for Th1-type cytokines (e.g., IFN-γ) were upregulated (Fig. 4). In addition, the analysis of CD4+ββ T cells isolated from the MLNs of IL-4-specific mAb-treated mice resulted in the alteration of cytokine expression from a dominant Th2 to a Th1 type. The reduction of Th2-type cytokine production and the enhancement of Th1-type cytokine production in mice treated with anti-IL-4 mAb were further confirmed at the protein level through ELISA analysis of secreted Th1 and Th2 cytokines (Fig. 5). Thus, in vitro stimulation of colonic lymphocytes isolated from anti-IL-4 mAb-treated mice with anti-CD3 or anti-TCR-β resulted in the decrease of Th2 cytokines (e.g., IL-4 and IL-6) and the increase of IFN-γ synthesis. In contrast, treatment with mock Ab resulted in high levels of Th2 cytokine production. These results demonstrate that a shift from a Th2- to Th1-type response was induced in anti-IL-4 mAb-treated TCR-α−/− mice.

Alteration of the Aberrant Immune Response by Anti-IL-4 mAb Treatment Resulted in the Prevention of Mucosal Inflammation in TCR-α−/− Mice. We next investigated the effect
of anti–IL-4 mAb on the induction of IBD in the TCR-\(\alpha^\text{–}\) mice. Approximately 60% of TCR-\(\alpha^\text{–}\) mice treated with mock Ab or left untreated were observed to develop the morphological changes that have been reported previously to be typical of IBD, including anorectal prolapse, diarrhea, and the weight loss and hunched posture characteristic of wasting syndrome (2, 10). In contrast, the mice treated with anti–IL-4 mAb showed no significant weight loss (Fig. 6). Histological examination of the intestinal LP of TCR-\(\alpha^\text{–}\) mice treated with anti–IL-4 mAb showed more elongation of epithelial villi and markedly less infiltration of inflammatory cells than in that of mice treated with mock Ab (Fig. 7). Because a reduction in the number of goblet cells has also been reported in the colon of humans with IBD (20), we stained tissue sections prepared from the colon of anti–IL-4 mAb– and mock Ab–treated TCR-\(\alpha^\text{–}\) mice with alcian blue in order to detect goblet cells. As in the colons of humans suffering from IBD, the number of goblet cells in colons of mock Ab–treated mice was reduced. In contrast, the number of goblet cells was almost normal in the colon of TCR-\(\alpha^\text{–}\) mice treated with anti–IL-4 mAb (Fig. 8). These findings suggest that the inhibition of the Th2-type response by anti–IL-4 mAb treatment results in the prevention of mucosal inflammation in TCR-\(\alpha^\text{–}\) mice.

**Discussion**

The mucosal immune system consists of several immune components, including \(\alpha/\beta\) and \(\gamma/\delta\) T cells, IgA B cells, macrophages, dendritic cells, and epithelial cells, that form a molecular and cellular inter/intranet that provides a protective barrier against pathogens and environmental antigens in the gut (21–23). Under normal conditions, the mucosal immune system also properly regulates the intestinal mucosa. However, in those suffering from IBD, the mucosal immune system, and more particularly the T cell–dependent regulatory system, is disrupted (1, 3). In TCR-\(\alpha^\text{–}\) mice, CD4+ \(\beta^\text{+}\) T cells are considered to play a key role in the induction of IBD (9, 10, 13).

The results of this study demonstrated two new and important points regarding the role of Th1- and Th2-type cells in the development of IBD. In all murine IBD models used, including specific gene-manipulated and hapten-induced mice, a common observation was that the enhancement of Th1-type activity was associated with disease development (24–26). However, previous studies have posited that Th2-like responses are involved in the development of colon inflammation in human ulcerative colitis (27–31). Our study directly demonstrates that CD4+ \(\beta^\text{+}\) T cells isolated from the inflamed colon possess characteristics of Th2-type cells based on their cytokine profile at the mRNA and protein levels (Figs. 4 and 5). Further, it was shown that alteration of the cytokine profile from a Th2 to a Th1 type by treatment with anti–IL-4 mAb resulted in the prevention of colitis in TCR-\(\alpha^\text{–}\) mice (Figs. 4 and 5). The decrease of IL-4–dependent IgG1 and IgG2b Ab responses further confirmed that anti–IL-4 mAb treatment inhibited Th2-type responses (Fig. 1 A). These two important findings suggest that aberrant mucosal Th2-type cells are involved in the development of chronic inflammation in the intestinal tract. Two very recent studies support this conclusion by demonstrating that Th2-type CD4+ T cells play a major role in the development of hapten-induced murine colitis (32, 33).

IL-4 initially received attention as an enhancer of DNA synthesis in mouse B lymphocytes (34). Since then, extensive molecular and immunological investigations have established IL-4 as a biologically potent and essential cytokine for B cell development and responses, including those of IgE and IgG1 (35). Further, this cytokine has been
Inhibition of IL-4 Synthesis Prevents Th2 Cell–induced IBD

shown to play an essential role in the generation of Th2-type from Th0-type cells (35). Although IL-4 is considered to be a hallmark cytokine for Th2-type T cells, it should be noted that other immunologically competent cells such as mast cells, basophils, γδ T cells, and NK1.1+ T cells can produce this cytokine (35–40). NK1.1+CD4+ T cells have been shown to be a particularly important source of IL-4 (37). Histological analysis with alcian blue and flow cyto-
metric analysis using mAb specific to NK1.1 detected only a small number of mast cells and NK1.1+ T cells in TCR-α−/− mice (data not shown). Although our previous and present results clearly demonstrate that CD4+β T cells are the primary source for the production of IL-4 in TCR-α−/− mice with IBD, it is still possible that a minor population of NK1.1+CD4+ T cells provides an alternative source of the cytokine. When mucosal γ/δ T cells were isolated from the intestinal tract of TCR-α−/− mice with IBD for the analysis of cytokine production, no specific message for IL-4 was detected (data not shown). Therefore, the population of CD4+β T cells is most likely the major source of IL-4.

In regard to the increased B cell responses in these diseased TCR-α−/− mice, Th2 cytokines produced by CD4+β T cells are responsible for the activation of auto- and food antigen–specific IgG, IgE, and IgA Ab production pathways (10). IL-4 is a well-known switch factor for IgE and food antigen–specific IgG1 and IgE, and IgA Ab responses were also upregulated in TCR-α−/− mice with IBD (10). A similar pattern of response was also observed in TCR-α−/− mice treated with mock Ab. The increased B cell responses in TCR-α−/− mice with IBD could be explained by our present finding that these CD4+β T cells were capable of producing IL-5, IL-6, and IL-10 in addition to IL-4 (Fig. 4). These Th2-type cytokines further support the production of Abs, including those of the IgA isotype, in TCR-α−/− mice. In fact, studies using both murine and human experimental systems have shown that IL-5, IL-6, and IL-10 are IgA-enhancing cytokines (20, 21). When TCR-α−/− mice were treated with anti–IL-4 mAb, the levels of all the isotypes of Abs were significantly decreased in their serum and fecal extracts. Inasmuch as our results demonstrated that anti–IL-4 mAb treatment altered the cytokine profile of CD4+β T cells from a Th2 to a Th1 type (Figs. 4 and 5), it is most likely that an abrogation of Th2 cytokine synthesis resulted in the reduction of B cell development.

It is not yet known whether Abs against auto- and food antigens play a pathological role, much less by what means they might do so. Several reports have provided evidence that the levels of autoantibodies (autoAbs, e.g., anti-goblet cell, antitrypsin, and anticolon autoAbs) were increased in the colon of humans suffering from IBD and have suggested that these autoAbs are the causative pathogens for the destruction of mucosal tissues by Ab-dependent cell-mediated cytotoxicity (40–44). Therefore, one possible mechanism for the prevention of IBD by anti–IL-4 mAb could be the reduction of autoAb-producing B cell responses. However, a separate study demonstrated that the disease process accelerated in double knockout mice, which lacked both Ig μ and TCR α chains and which were generated by crossing TCR-α−/− and Ig-μ−/− deficient mice (45). It also showed that, in some cases, the removal of B cells worsened the symptoms of colitis. The results of that study suggest that Abs play a protective rather than a pathological role in the development of mucosal inflammation. It remains to be examined whether aberrant B cells and their derived Abs are involved in the initiation of the inflammatory process in IBD.

IL-4 has been shown to directly regulate intestinal epithelial cell functions. For example, IL-4 can regulate the growth of epithelial cells. It is also capable of disrupting the barrier function of the intestinal epithelium, of enhancing the adherence of neutrophils to the epithelia, and of upregulating transepithelial neutrophil migration (46). Overproduction of IL-4 in the intestinal epithelium may disrupt immunological homeostasis between the mucosal immune system and environmental antigens, including gut lumen microorganisms, allowing recruitment of inflammatory cells for the initiation of disease. Therefore, a second possible mechanism for the prevention of colitis development by mAb treatment might be the direct inhibition of IL-4 effects on the intestinal epithelial cells.

IL-4–specific mAb treatment directly inhibited the development of Th2-type aberrant CD4+β T cells, which are thought to be directly involved in the induction of IBD. For example, Th2-dominated conditions such as those characteristic of IFN-γ−/− mice have been shown to be conducive to the development of a delayed-type hypersensitivity reaction (47, 48), and Th2-type cells are thought to contribute to the development of autoimmune diseases (49, 50). Finally, a recent study from another group provided direct evidence that IL-4 produced by Th2-type CD4+β T cells was associated with the development of murine colitis by showing the reduction of disease incidence in mice of the TCR-α−/− and IL-4−/− double knockout models (51).

In summary, this study has demonstrated that the pathological ability of CD4+β T cells to induce IBD is inhibited by their alteration from a Th2 to a Th1 type. It has also shown that the treatment of TCR-α−/− mice with anti–IL-4 mAb resulted in the blockage of colitis formation.
References

1. Powrie, P. 1995. T cells in inflammatory bowel disease: protective and pathogenic roles. Immunity. 3:171–174.

2. Mombaerts, P., E. Mizoguchi, M.J. Grusby, L.H. Gimlich, A.K. Bhan, and S. Tonegawa. 1993. Spontaneous development of inflammatory bowel disease in T cell receptor mutant mice. Cell. 75:274–282.

3. Strober, W., and R.O. Elfrhardt. 1993. Chronic intestinal inflammation: an expected outcome in cytokine or T cell receptor mutant mice. Cell. 75:203–205.

4. Sadlack, B., H. Merz, A. Schimpl, A.C. Feller, and I. Horak. 1993. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell. 75:253–261.

5. Watanabe, M., Y. Ueno, T. Yajima, S. Okamoto, T. Hayashi, M. Yamazaki, Y. Iwao, H. Ishii, S. H Abe, M. Uehira, et al. 1998. Interleukin 7 transgenic mice develop chronic colitis with disease interleukin 7 protein accumulation in the colonic mucosa. J. Exp. Med. 187:389–402.

6. Kühn, R., J. Jöhler, D. Rennick, K. Rajewsky, and W. Müller. 1993. Interleukin-10-deficient mice develop chronic enterocolitis. Cell. 75:263–274.

7. Rudolph, U., M.J. Finegold, S.S. Rich, G.R. Harriman, Y. Srinivasan, P. Brabet, G. Boulay, A. Bradley, and L. Birnbaum. 1995. Ulcerative colitis and adenocarcinoma of the colon in Gγδ-deficient mice. Nat. Genet. 10:143–150.

8. Morrissey, P.J., K. Charrier, S. Braddy, D. Liggitt, and J.D. Watson. 1993. CD4 T cells that express high levels of CD45RB induce wasting disease when transferred into congenic severe combined immunodeficient mice. Disease development is prevented by cotransfer of purified CD4 T cells. J. Exp. Med. 178:237–244.

9. Mizoguchi, A., E. Mizoguchi, C. Chiba, G.M. Spiekermann, S. Tonegawa, C. Nagler-Ander son, and A.K. Bhan. 1996. Cytokine imbalance and autoantibody production in T cell receptor-α mutant mice with inflammatory bowel disease. J. Exp. Med. 183:847–856.

10. Takahashi, I., H. Kiyono, and S. Hamada. 1997. CD4 T cell population mediates development of inflammatory bowel disease in T cell receptor-α chain-deficient mice. Gastroenterology. 112:1876–1886.

11. Dianda, L., A. Gulbranson-Judge, W. Pao, A.C. Hayday, I.C.M. MacLennan, and M.J. Owen. 1996. Germinal center formation in mice lacking αβ T cells. Eur. J. Immunol. 26:1603–1607.

12. Viney, J.L., L. Dianda, S.J. Roberts, L. Wen, C.A. Mallick, A.C. Hayday, and M.J. Owen. 1994. Lymphocyte proliferation in mice congenitally deficient in T cell receptor-αβ+ T cells. Proc. Natl. Acad. Sci. USA. 91:11948–11952.

13. Takahashi, I., H. Iijima, R. Katashima, M. Itakura, and H. Kiyono. 1999. Clonal expansion of CD4 TCRβ+ T cells in TCR-α chain-deficient mice by gut-derived antigens. J. Immunol. 162:1843–1850.

14. deVos, T., and T.A. Dick. 1991. A rapid method to determine the isotype and specificity of coproantibodies in mice infected with Trichinella or fed cholera toxin. J. Immunol. Methods. 141:285–289.

15. Takahashi, I., M. Marinoro, H. Kiyono, R.J. Jackson, I. Nakagawa, K. Fujihashi, S. Hamada, K.L. Bost, and J.R. McGhee. 1996. Mechanisms for mucosal immunogenicity and adjuvancy of Escherichia coli heat-labile enterotoxin. J. Infect. Dis. 173:627–635.

16. Aicher, W., K. Fujihashi, M. Yamamoto, H. Kiyono, A.M. Pitts, and J.R. McGhee. 1992. Effects of the lpr/lpr mutation on T and B cell populations in the lamina propria of small intestine, a mucosal effector site. Int. Immunol. 4:959–968.

17. Brenner, C.A., A.W. Tam, P.A. Nelsing, E.G. Engleman, N. Suzuki, K.E. Fry, and J.W. Larri ck. 1989. Messenger amplification phenotyping (MAPPIng): a technique to simultaneously measure multiple mRNAs from small numbers of cells. Biotechniques. 7:1096–1103.

18. Fujihashi, K., M. Yamamoto, J.R. McGhee, K.W. Beagley, and H. Kiyono. 1993. Function of αβ TCR-γ intestinal intraepithelial lymphocytes Th1- and Th2-type cytokine production by CD4+CD8- and CD4-CD8+ T cells for helper activity. Int. Immunol. 5:1473–1481.

19. Yamabayashi, S. 1987. Periodic acid-Schiff-alcian blue: a method for the differential staining of glycoproteins. Hösthem. J. 19:565–571.

20. Evans, C.M., A.D. Phillips, J.A. Walker-Smith, and T.T. MacDonald. 1992. Activation of lamina propria T cells induces crypt epithelial proliferation and goblet cell depletion in cultured human fetal colon. Gastroenterology. 103:230–235.

21. Mestecky, J., and J.R. McGhee. 1987. Immunoglobulin A (IgA): molecular and cellular interactions involved in IgA biosynthesis and immune response. Adv. Immunol. 40:153–245.

22. Kiyono, H., J. Bienenstock, J.R. McGhee, and P.B. Ernst. 1992. The mucosal immune system: features of inductive and effector sites to consider in mucosal immunization and vaccine development. Rev. Immunol. 4:54–62.

23. Mowat, A.M., and J.L. Viney. 1997. The anatomical basis of intestinal immunity. Immunol. Rev. 156:145–166.

24. Elson, C.O., K.W. Beagley, A.T. Sharmanov, K. Fujihashi, H. Kiyono, G.S. Tennyson, Y. Cong, C.A. Black, B.W. Ridwan, and J.R. McGhee. 1996. Hapten-induced model of murine inflammatory bowel disease. 157:2174–2185.

25. Bregenholt, S., and M.H. Claesson. 1998. Increased intracellular Th1 cytokines in scid mice with inflammatory bowel disease. Eur. J. Immunol. 28:379–389.

26. Powrie, F., J. Carlino, M.W. Leach, S. Mauze, and R.L. Coffman. 1996. A critical role for transforming growth factor-β but not interleukin 4 in the suppression of T helper type 1-mediated colitis in CB45R B+ CD4 T cells. J. Exp. Med. 183:2669–2674.

27. Fuss, I., M. Neurath, M. Boirivant, J.S. Klein, C. de la Motte, S.A. Strong, C. Fiocchi, and W. Strober. 1996. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-γ, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 157:1261–1270.

28. Sartor, R.B. 1994. Cytokines in intestinal inflammation: pathophysiological and clinical considerations. Gastroenterology. 106:533–539.

29. Breese, E., C.P. Braegger, C.J. Corrigan, J.A. Walker-Smith, and T.T. MacDonald. 1993. Interleukin-2- and interferon-γ-secreting T cells in normal and diseased human intestinal mucosa. Immunology. 78:127–131.

30. Niessner, M., and B.A. Volk. 1995. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin. Exp. Immunol. 101:428–435.

31. Parronchi, P., P. Romagnani, F. Annuzziato, S. Sampognaro, A. Becchio, L. Giannarini, E. Maggi, C. Pupilli, F. Tonelli, and S. Romagnani. 1997. Type I T helper cell predominance
and interleukin-12 expression in the gut of patients with Crohn’s disease. Am. J. Pathol. 150:823–832.

32. Dohi, T., K. Fujihashi, P.D. Rennert, K. Iwatani, H. Kiyono, and J.R. McGhee. 1999. Hapten-induced colitis is associated with colonic patch hypertrophy and T helper cell 2-type responses. J. Exp. Med. 189:1169–1180.

33. Boirivant, M., I.J. Fuss, A. Chu, and A. Strober. 1998. Oxazolone colitis: a murine model of T helper cell type 2 colitis treatable with antibodies to interleukin-4. J. Exp. Med. 188:1929–1939.

34. Howard, M., J. Farrar, M. Hilfiker, B. Johnson, K. Takatsu, T. Hamaoka, and W.E. Paul. 1982. Identification of a T cell–derived B cell growth factor distinct from interleukin-2. J. Exp. Med. 155:914–923.

35. Paul, W.E. 1991. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood. 77:1859–1870.

36. Bendelac, A., M.N. Rivera, S.-H. Park, and J.H. Roark. 1997. Mouse CD1-specific NK1 T cells: development, specificity and function. Annu. Rev. Immunol. 15:535–562.

37. Yoshimoto, T., and W.E. Paul. 1994. CD4$^+$ NK1.1$^+$ T cells promptly produced IL-4 in response to in vivo challenge with anti-CD4. J. Exp. Med. 179:1285–1295.

38. O’Garra, A. 1998. Cytokines induce the development of functionally heterogeneous T helper cell subsets. Immunity. 8:275–283.

39. Ferrick, D.A., M.D. Schrenzel, T. Mulvania, B. Hsieh, W.G. Ferlin, and H. Lepper. 1995. Differential production of interferon-gamma and interleukin-4 in response to Th1- and Th2-stimulating pathogens by gamma delta T cells in vivo. Nature. 373:255–257.

40. Zuany-Amorim, C., C. Ruffié, S. Hailé, B.B. Vargaftig, P. Pereira, and M. Pretolani. 1998. Requirement for γδ T cells in allergic airway inflammation. Science. 280:1265–1267.

41. Brantzaeg, P. 1995. Autoimmunity and ulcerative colitis: can two enigmas make sense together? Gastroenterology. 109:307–322.

42. Geng, X., L. Biancone, H.H. Dai, J.J.-C. Lin, N. Yoshizaki, A. D'agupta, F. Pallone, and K.M. Das. 1998. Tropomyosin isoforms in intestinal mucosa: production of autoantibodies to tropomyosin isoforms in ulcerative colitis. Gastroenterology. 114:912–922.

43. Folvaczny, C., N. Noehl, K. Tschop, S.P. Endres, W. Heldwein, K. Loeschke, and H. Fricke. 1997. Goblet cell autoantibodies in patients with inflammatory bowel disease and their first-degree relatives. Gastroenterology. 113:101–106.

44. Hibi, T., S. Aiso, M. Ishikawa, M. Watanabe, T. Yoshida, S. Tsuru, and M. Tsutshiya. 1982. Anti-colon antibody and lymphocytopenia antibody in ulcerative colitis. Clin. Exp. Immunol. 49:75–80.

45. Mizoguchi, A., E. Mizoguchi, R.N. Smith, F.I. Preffer, and A.K. Bhan. 1997. Suppressive role of B cells in chronic colitis of T cell receptor α mutant mice. J. Exp. Med. 186:1749–1756.

46. Colgan, S.P., M.B. Rensnick, C.A. Parcos, C. Delp-Archer, D. McGuirk, A.E. Barcarra, P.F. Weller, and J.L. Madara. 1994. IL-4 directly modulates function of a model human intestinal epithelium. J. Immunol. 153:2122–2129.

47. Cooper, A.M., D.K. Dalton, T.A. Stewart, J.P. Griffin, D.G. Rassell, and I.M. Orme. 1993. Disseminated tuberculosis in interferon-γ gene-disrupted mice. J. Exp. Med. 178:2243–2247.

48. Kweon, M.-N., K. Fujihashi, J.L. VanCott, K. Higuchi, M. Yamamoto, J.R. McGhee, and H. Kiyono. 1998. Lack of orally induced systemic unresponsiveness in IFN-γ knockout mice. J. Immunol. 160:1687–1693.

49. Mavalia, C., C. Scaletti, P. Romagnani, A.M. Carrosso, A. Pignone, L. Emmi, C. Pupilli, G. Pizzolo, E. Maggi, and S. Romagnani. 1997. Type 2 helper T-cell predominance and high CD30 expression in systemic sclerosis. Am. J. Pathol. 151:1751–1758.

50. Lafaille, J.J., F.V. de Keere, A.L. Hsu, J.L. Baron, W. Haas, C.S. Raine, and S. Tonegawa. 1997. Myelin basic protein-specific T helper 2 (Th2) cells cause experimental autoimmune encephalomyelitis in immunodeficient hosts rather than protect them from the disease. J. Exp. Med. 186:307–312.

51. Mizoguchi, A., E. Mizoguchi, and A.K. Bhan. 1999. The critical role of interleukin 4 but not interferon gamma in the pathogenesis of colitis in T-cell receptor α mutant mice. Gastroenterology. 116:320–326.